turning us is martin henrichs, head of health care m&a at ubs.k with you on bloomberg. are we going to see a flurry of activity as some of these big companies try and look at their pipeline and either streamline or bulk up in places where they should? martin: first of all, concerning in the coronast environment, you might recall what johnson & johnson said a few months ago. one thing i know for certain is we are going to be 100% itcisely wrong, and i think is relative -- it is relatively difficult to forecast. the other thing, with the core trials happened in -- you mentioned johnson & johnson. the question that we will have this and the trials, such as unity,f the duration of aspects of certain patient populations -- we will not see a one-size-fits-all approach for covid vaccines, but we will see multiple approaches and it is relatively difficult to forecast when we will end up with a pipeline -- francine: there seems to be huge disparities because of health stocks. overall, how does covid-19 change the winners and losers in the current crisis?